Phase-III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

Trial Profile

Phase-III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2017

At a glance

  • Drugs Everolimus (Primary) ; Anastrozole; Exemestane; Goserelin; Goserelin; Letrozole; Leuprorelin; Leuprorelin; Tamoxifen
  • Indications Breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jan 2016 Planned number of patients changed from 3500 to 1900, according to ClinicalTrials.gov record.
    • 26 Jan 2016 Planned End Date changed from 1 Jan 2027 to 1 Jan 2030, according to ClinicalTrials.gov record.
    • 26 Jan 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2022, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top